Adverse prognostic factor ID'd in operable breast cancer

Adverse prognostic factor ID'd in operable breast cancer
For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 is an adverse prognostic factor, according to a study published online Sept. 4 in The Oncologist.

(HealthDay)—For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 (HER-2 2+/HER-2) is an adverse prognostic factor, according to a study published online Sept. 4 in The Oncologist.

Valentina Rossi, M.D., from the Institute for Cancer Research and Treatment in Candiolo, Italy, and colleagues compared the clinical outcomes of 1,150 women (median age, 58 years) with operable breast cancer who were not receiving adjuvant . Patients were stratified according to a common HER-2 testing algorithm.

Of the women, 40 percent were considered HER-2 0+; 39 percent were HER-2 1+; 10 percent were HER-2 2+/HER-2; and 11 percent were HER-2+ (3+ or HER-2+) by fluorescence in situ hybridization. The researchers found that, on multivariate analysis, a HER-2 2+/HER-2 status correlated with worse disease-free survival, compared with a HER-2 0 or 1+ status. A HER-2 2+/HER-2 status showed a time-dependent effect on the probability of disease-free survival, with an initial advantage that lessened every year by a factor of 1.649, compared with a HER-2+ status.

"A HER-2 2+/HER-2status is an adverse prognostic factor in patients with operable ," the authors write. "Because of suggestions from randomized trials that the benefits of adjuvant trastuzumab may not be limited to patients with HER-2+ tumors, patients with a HER-2 2+/HER-2status are ideal candidates for studies testing this hypothesis."

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Gene test aids cancer profile

6 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

How a common antacid could lead to cheaper anti-cancer drugs

23 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.